The family caregivers of PwD exhibited a fair QoL, with a score of 29.01 ± 4.059. 5 key findings →
Design: cross-sectional Participants: 150 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Research
27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
The prevalence of caregiver burden was 28.9%. 5 key findings →
Design: cross-sectional Participants: 602 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Data indicated that participants' needs fluctuated, with 3 key time points of heightened need: dementia diagnosis, in-home care, and transition into residential care. 3 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
This protocol will outline the scoping review of current literature on caregiver-involved reminiscence for persons with dementia. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
All Hispanic/Latino immigrant adults, regardless of age at migration, have a cognitive health disadvantage (at each visit and over time) relative to U.S./mainland-born Hispanic/Latino individuals. 5 key findings →
Participants: 16,415 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
50/100
, respectively (p-values < 0.05), with p-tau217 demonstrating the highest classification accuracy for Aβ-PET status (AUC = 0.94). 4 key findings →
Participants: 113 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
We assessed 452,718 patients (mean age: 67.16 years). 3 key findings →
Design: cohort study Participants: 452,718 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
After PSM, 7914 participants were analyzed (3957 consumers; 3957 non-consumers). 5 key findings →
Participants: 7,914 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In this cohort, 28 participants developed Alzheimer's dementia, 5 frontotemporal dementia, 2 Lewy body dementia, and 2 vascular dementia during the follow-up. 5 key findings →
Participants: 56 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Per- and polyfluoroalkyl substances (PFAS) are ubiquitous persistent organic pollutants. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Among 360,014 individuals with psoriasis and 1,799,617 without, psoriasis was associated with a small increased risk of all-cause dementia (adjusted hazard ratio [aHR] 1.06, 95% CI 1.04-1.08; absolute rate difference 24 per 100,000 person-years). 5 key findings →
Participants: 360,014 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
PWAbS revealed elevated gross autoantibody levels in AD and DLB patients compared to CNIs. 5 key findings →
Design: longitudinal study Participants: 35 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
50/100
Our findings indicate that using location-based trajectory metrics with clinical measures significantly improves the predictability of motor agitation beyond individual baselines. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Model scores two standard deviations below the mean had 4 months increased survival (two standard deviations below had 3 months decreased survival). 5 key findings →
Participants: 802 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
50/100
Dementia, particularly Alzheimer's disease (AD), presents a growing global health challenge characterized by cognitive decline, behavioral changes, and loss of independence. 1 key finding →
Participants: 2,878 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The progressive nature of dementia necessitates early detection strategies capable of identifying preclinical cognitive decline. 1 key finding →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
This study developed machine learning models to predict Aβ positivity in Alzheimer’s disease by integrating early-phase 18 F-Florbetaben PET and clinical data to improve diagnostic accuracy. 2 key findings →
Participants: 176 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We identified 471 proteins with significant interaction effects between T2D and dementia risk. 5 key findings →
Participants: 2,920 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Most studies suggest depression may contribute to neurodegeneration, but clinical, neuroimaging, and longitudinal evidence also support its role as a prodrome or consequence, indicating a bidirectional relationship. 2 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In preclinical studies, partial or complete sleep deprivation produced inflammation, oxidative stress, as well as increased tau hyperphosphorylation and amyloid-β burden. 2 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
When risk factors were evaluated independently, we found less early-life education, mid-life hearing loss and diabetes, and late-life social isolation and visual loss associated with increased odds for dementia. 5 key findings →
Design: cross-sectional Participants: 5,526 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Education, smoking, diabetes, depression, physical activity and social isolation were associated with a 1.13-1.55 times increased risk of dementia. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The identification of biomarkers predicting the burden of brain alpha-synuclein (α-syn) pathology in vivo represents a research priority in Lewy body disease (LBD). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
50/100
Of 11 subjects with average AUCs above 500,000 units, 7 (64%) developed a central LBD compared to 1 of 20 (5%), with AUCs below the cutoff value (P = 0.0011 by log-rank test). 3 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
= 0.029). Despite the absence of overt nOH, patients with DLB show covert dysautonomia encompassing adrenergic, parasympathetic, and sudomotor dysfunction, highlighting the importance of standardized autonomic evaluation. 3 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →